顺铂加吉西他滨与顺铂加长春瑞滨一线治疗晚期非小细胞肺癌的对照研究被引量：7

Comparative study of cisplatin plus gemcitabine versus cisplatin plus vinorelbine in patients with advanced stage non-small cell lung cancer

暂未订购

导出

摘要目的:探讨顺铂(DDP)加吉西他滨(GEM)与顺铂加长春瑞滨(NVB)治疗晚期非小细胞肺癌(NSCLC)的疗效、不良反应。方法:66例NSCLC患者分别接受GEM/DDP方案与NVB/DDP方案化疗GEM/DDP(GP)化疗方案:GEM1000mg.m-2d1、8DDP75mg.m-2,总剂量分为3d使用,dl^3NVB/DDP(NP)化疗方案:NVB25mg.m-2d1、8;DDP80mg.m-2,总剂量分为3d使用,d1~3。21d为一周期,所有病例均接受2个周期以上的治疗。观察两组的近期有效率、中位生存时间(MST)、1年生存率、不良反应。结果:GP和NP方案的有效率分别为41.6%和36.7%,中位生存期分别为10.3个月和9.6个月,1年生存率分别为44.4%和40.0%(P=0.33)。GP组的III^IV级血小板减少47.2%,显著高于NP组6.6%(P<0.01),而NP组的中性粒细胞减少高于GP组,分别为60%和33.3%(P<0.05)。结论:GP和NP方案治疗晚期NSCLC疗效相当,但毒性反应略有差别。 AIM： To explore the differences of efficacy and side-effects in advanced stage non-small cell lung cancer （NSCLC） patients treated with gemcitabine plus cisplatin or vinorelbine plus cisplatin. METHODS： Eligible patients were randomly assigned to GP （gemcitabine ＋ cisplatin） group or NP （ vinorelbine plus cisplatin） group. In GP group, 36 evaluable patients were treated with gemcitabine 1000 mg·m^-2 Ⅳ on day 1 and 8 and cisplatin 75 mg· m^-2 Ⅳ which was divided into 1 - 3 days dosing, in a 21 days per cycle manner. In NP group, 30 evaluable patients were treated with vinorelbine 25 mg·m^-2 Ⅳ on day 1 and 8 and cisplatin 80 mg·m^-2 Ⅳ which was divided into 1 - 3 days dosing, 21 days per cycle. All the patients at least received two cycles therapy. The response rate, median survival time （MST）, 1 year survival, and side-effects were observed. RESULTS： The response rates were 41.6% vs 36.7% ; MST were 10.3 months vs 9.6 months; 1 year survival rate were 44.4% vs 40.0% （ P = 0.33） in GP group and NP group, respectively. Ⅲ-Ⅳ grade thrombocytopenia toxicity incurred significantly higher in GP group than in NP group, with the occurrence rate being 47.2% vs 6.6% （P 〈0.01）. However, Ⅲ-Ⅳ grade granulocytopenia was significantly less incurred in GP group than in NP group, 33.3% vs 60.0% （P 〈0.05）. CONCLUSION： Our study demonstrates that GP （gemcitabine ＋ cisplatin） regime and NP （vinorelbine plus cisplatin） regime ate equivalent in treating advanced NSCLC, however they have few different toxicities.

作者赵文英吉兆宁

机构地区皖南医学院弋矶山医院肿瘤内科

出处《中国临床药理学与治疗学》 CAS CSCD 2006年第12期1408-1411,共4页 Chinese Journal of Clinical Pharmacology and Therapeutics

关键词非小细胞肺癌化疗吉西他滨长春瑞滨顺铂 non-small cell lung cancer chemotherapy gemcitabine vinorelbine cisplatin

分类号 R969 [医药卫生—药理学] R730.53 [医药卫生—肿瘤]

引文网络
相关文献

参考文献13

1Greenlee RT,Murray T,Bolden S,Wingo PA.Cancer statistics[J].CA Cancer J Clin,2000;50:7-33
2Mok TS,Steinberg J,Chan AT,Yeo WM,Hui P,Leung TW,et al.APPlication of the internation-al prognostic index in a study of Chinese patients with non-Hodgkin's lymphoma and a high incidence of primary extranodal lymphoma[J].Cancer,1998;82:2439-48
3The Non-Small Cell Lung Cancer Collaborative Group.Chemotherapy in non-small cell lung cancer:A meta-analysis using up dated data on individual patients from 52 randomized clinical trials[J].BMJ,1995,311:899-909
4http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf(2006 Vision 2)
5D'Addario G,Pintilie M,Leighl NB,Feld R,Cerny T,Shepherd FA.Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell LungCancer:A Meta-Analysis of the Published Literature[J].J Clin Oncol 2005;23:2926-36
6Zojwalla NJ,Raftopoulos H,Gralla RJ,Gralla RJ.Are cisplatin and carboplatin equivalent in the treatment of non-small cell lung cancer? Results of a comprehensive review of randomized studies in over 2300 patients[J].Proc Am Soc Clin Oncol,2004;23:abs7068
7Depierre A,Chastang C,Quoix E,Lebeau B,Blanchon F,Paillot N,et al.Vinorelbine versus vincrelbine plus cisplatin in advanced non-small cell lung cancer[J].Ann Oncol,1994;5:37-42
8Wozniak AJ,Crowley JJ,Balcerzak SP,Weiss GR,Spiridonidis CH,Baker LH,et al.Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer:A Southwest Oncology Group study[J].J Clin Oncol,1998,16:2459-65
9Anderson H,Hopwood P,Stephens RJ,Thatcher N,Cottier B,Nicholson M,et al.Gemcitabine plus best supportive care(BSC) vs BSC in inoperable non-small cell lung cancer---a randomized trial with quality of life as the primary outcome[J].Br J Cancer,2000;83:447-53
10Sandler AB,Nemunaitis J,Denham C,von Pawel J,Cormier Y,Gatzemeier U,et al.Phase Ⅲ trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer[J].J Clin Oncol,2000;18:122-30